Regeneron Pharma (REGN) Shares Up After Jim Cramer Called It a Good Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that focuses on a variety of ailments involving the neurological, cardiovascular, and other ailments. The firm is focused on developing weight loss drugs that enable users to retain lean muscle mass while shedding weight. Over the year, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s shares are up by 16.32%, and since Cramer discussed the firm in March 2025, they are up by 10.6%. The stock closed 11.8% higher on October 28th as the firm reported its third-quarter earnings report. The results saw the firm post $3.75 billion in revenue and $11.83 in quarterly profit per share to beat analyst estimates of $3.59 billion and $9.59. Year-to-date, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s shares are down by 4.9%. A notable dip came in January when the shares dipped significantly between the 9th and 16th. Bank of America discussed the firm in January as it bumped Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s rating to Buy from Underperform and increased the share price target to $860 from $627. Here’s what Cramer had said about the firm in March 2025 on Mad Money:

“I will tell you this, Regeneron, I want you to own it. I think it’s doing better than people realize. That is a good stock.”

Regeneron Pharma (REGN) Shares Up After Jim Cramer Called It a Good Stock

While we acknowledge the risk and potential of REGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than REGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.